Evidence map›Paper›PMID 22855518›Full record

ArticleJournal of clinical microbiology2012

Isolation and identification of Kroppenstedtia eburnea isolates from multiple patient samples.

Adam P Barker, Keith E Simmon, Sam Cohen, E Susan Slechta, Mark A Fisher, Robert Schlaberg

Erratum issuedAbstract read
In one paragraph

Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Draft Genome Sequence of Kroppenstedtia sanguinis X0209Microbiology resource announcements · 2019
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

6 authors.

Adam P BarkerUniversity of Utah School of Medicine, Salt Lake City, Utah, USA.
Keith E Simmon
Sam Cohen
E Susan Slechta
Mark A Fisher
Robert Schlaberg

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No clinical isolates have been reported for the recently described thermoactinomycete Kroppenstedtia eburnea. Between 2006 and 2011, we obtained 14 clinical isolates from patients in 9 U.S. states. Here we report growth characteristics, 16S rRNA gene sequencing, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry-based identification, and antimicrobial susceptibility profiles of this recently described organism.

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsBacillalesCluster AnalysisDNA, BacterialDNA, RibosomalFemaleGram-Positive Bacterial InfectionsHumansInfantMaleMicrobial Sensitivity TestsMiddle AgedPhylogenyAnti-Bacterial AgentsDNA, BacterialDNA, RibosomalRNA, Ribosomal, 16S

Identifiers

PMID22855518
PMCPMC3457443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.